Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab
about
The Response of Macrophages and Neutrophils to Hypoxia in the Context of Cancer and Other Inflammatory DiseasesBeyond evidence-based data: scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinomaDevelopment, Maintenance, and Reversal of Multiple Drug Resistance: At the Crossroads of TFPI1, ABC Transporters, and HIF1Progress toward overcoming hypoxia-induced resistance to solid tumor therapyRelationship between hypoxia and response to antiangiogenic therapy in metastatic colorectal cancerBile acids destabilise HIF-1α and promote anti-tumour phenotypes in cancer cell modelsInduction of cellular prion protein (PrPc) under hypoxia inhibits apoptosis caused by TRAIL treatment.Visualizing the antivascular effect of bortezomib on the hypoxic tumor microenvironment.Strong Expression of Hypoxia-Inducible Factor-1α (HIF-1α) Is Associated with Axl Expression and Features of Aggressive Tumors in African Breast Cancer.Brusatol inhibits HIF-1 signaling pathway and suppresses glucose uptake under hypoxic conditions in HCT116 cells.Systematic Drug Screening Identifies Tractable Targeted Combination Therapies in Triple-Negative Breast Cancer.HIF-1 in cancer therapy: two decade long story of a transcription factor.Bortezomib-resistance is associated with increased levels of proteasome subunits and apoptosis-avoidanceTargeting adipose tissue in the treatment of obesity-associated diabetes.The evolving role of monoclonal antibodies in the treatment of patients with advanced renal cell carcinoma: a systematic review.Docosahexaenoic Acid-mediated Inhibition of Heat Shock Protein 90-p23 Chaperone Complex and Downstream Client Proteins in Lung and Breast Cancer.Tissue and imaging biomarkers for hypoxia predict poor outcome in endometrial cancer.Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma by combination with the human immunodeficiency virus (HIV)-protease inhibitors lopinavir or nelfinavir.The role of tumor microenvironment in resistance to anti-angiogenic therapy.Addition of bevacizumab to systemic therapy for locally advanced and metastatic nasopharyngeal carcinoma.
P2860
Q26749138-2BE7CF47-CF2D-4411-B5CA-1537B9F744F8Q26766240-514A5CDA-59FF-4032-B5AA-2213642CD179Q26778957-E740DBF5-2480-40D4-975C-94BF6B8BE94EQ26796405-7C9F1A80-36AE-4FF8-9257-191111AC7CDCQ28068654-93417D67-0C70-4D51-B3EE-9EECDAD44F7BQ28596213-E27407A6-8ECB-4AF3-A488-6A910371C4D7Q35741681-8373F987-B479-4118-A777-B654731E2F0AQ35790990-F39C32F4-C70D-4F06-A106-4A93D91CD720Q35892646-1CDDA966-6BB5-4223-A9A7-2E597DA79AF3Q37508566-58A7F71A-E0CC-4E39-87F8-4BB05667A42FQ38729732-22D55095-1242-41A1-8D09-8E2898999E32Q38737693-5C6B463C-9ECE-40D9-866C-F94A6D8411EAQ38739048-DC9D8CE0-096B-4647-968A-50B65A2C70A7Q38852204-C7428F76-68AC-4AE5-A5D3-F037049DE11CQ38910154-F3A45D43-F483-42A9-A86F-0BA8FFE29467Q39158772-65857595-7E87-4FF9-A8A3-846606AC963BQ42317488-FAC19008-6959-4810-96DA-FDF2EED1CBF2Q45324487-49F89266-338C-489B-9D90-500997FDD513Q52645823-C33ED208-4B69-4FEB-B8C3-AF4330947CD1Q55025647-0F3EFB6C-C1A2-41E0-B9FC-6F4B28BE621D
P2860
Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab
description
2014 nî lūn-bûn
@nan
2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Targeting hypoxia-inducible fa ...... of bortezomib plus bevacizumab
@ast
Targeting hypoxia-inducible fa ...... of bortezomib plus bevacizumab
@en
type
label
Targeting hypoxia-inducible fa ...... of bortezomib plus bevacizumab
@ast
Targeting hypoxia-inducible fa ...... of bortezomib plus bevacizumab
@en
prefLabel
Targeting hypoxia-inducible fa ...... of bortezomib plus bevacizumab
@ast
Targeting hypoxia-inducible fa ...... of bortezomib plus bevacizumab
@en
P2093
P2860
P50
P921
P356
P1433
P1476
Targeting hypoxia-inducible fa ...... of bortezomib plus bevacizumab
@en
P2093
Adrienne N Howard
Chaan S Ng
David Hong
Deeksha Vishwamitra
Edward F Jackson
Gerald S Falchook
Hesham M Amin
Jennifer J Wheler
Kenneth Hess
Kristie N Lawhorn
P2860
P304
10280-10292
P356
10.18632/ONCOTARGET.2163
P407
P577
2014-11-01T00:00:00Z